JANX: Janux Pharma Net earnings per share (EPS TTM)

Janux Therapeutics, Inc. (JANX) - corporate logo

Janux Therapeutics (JANX) is developing targeted therapies for oncology clinics, focusing on selective T-cell activators. The current trailing twelve-month net income per share reflects capital dynamics, where the value of -1.58 serves as the current metric. The development of immunotherapies entails immense risks and severe pressure from pharma behemoths. The startup's strategy is aimed at successful clinical trials of molecules to combat solid tumors.

JANX Janux Therapeutics Net earnings per share for the last 12 months (07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for Janux Corp (JANX)

Fundamental valuation:JANX - Janux Corp
Flagship merchandise of Janux Pharma

Earnings per share (EPS TTM) measures real profit generation efficiency, stripped of capital structure influence, allowing for an assessment of the fundamental return on each share of ownership. By analyzing the net income per share over the last 12 months, an investor can track the transition of Janux Therapeutics (JANX) from a cost-intensive targeted drug development phase to a stage of scalable commercialization and global dominance.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|RCUS: Net earnings per share (EPS TTM)|ZYME - Net earnings per share for the last four quarters|Earnings per share for the last twelve months tangotx.com|Net earnings per share for the last 12 months iovance.com (IOVA)|Earnings per share for the last twelve months Immatics NV (IMTX)|Net earnings per share for the last 12 months Xencor Corp XNCR|Compass Therapeutics Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Inc. REPL|LYEL - Earnings per share for the last twelve months|IPHA (innate-pharma.com) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen Ltd. (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)